Table 2 Predictive factors of good response
From: MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Variable | Responders (n = 78) | Non-responders (n = 130) | p |
|---|---|---|---|
Age (years) | 47.4 y | 45.9 y | 0.557 |
Gender (women) (n = 180) | 65 (36.1%) | 115 (63.9%) | 0.294 |
Aura (n = 36) | 18 (50%) | 18 (50%) | 0.088 |
CM (n = 186) | 69 (37.1%) | 117 (62.9%) | 0.727 |
EM (n = 22) | 9 (40.9%) | 13 (59.1%) | 0.907 |
MOH (n = 145) | 61 (42.1%) | 84 (57.9%) | 0.039 |
Prior BoNT/A (n = 198) | 74 (37.4%) | 124 (62.6%) | 0.867 |
Erenumab 70 mg (n = 140) | 51 (36.4%) | 89 (63.6%) | 0.760 |
Erenumab 140 mg (n = 68) | 27 (39.7%) | 41 (60.3%) | 0.648 |
Simultaneous BoNT/A (n = 57) | 34 (59.6%) | 23 (40.4%) |  < 0.001 |
Simultaneous oral preventives (n = 126) | 43 (34.1%) | 83 (65.9%) | 0.213 |